Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST (NCT02848651), an open-label, phase 2 trial that evaluated bTMB as a predi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Edward S., Velcheti, Vamsidhar, Mekhail, Tarek, Yun, Cindy, Shagan, Sarah M., Hu, Sylvia, Chae, Young Kwang, Leal, Ticiana A., Dowell, Jonathan E., Tsai, Michaela L., Dakhil, Christopher S. R., Stella, Philip, Jin, Yanling, Shames, David S., Schleifman, Erica, Fabrizio, David A., Phan, See, Socinski, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117143/
https://www.ncbi.nlm.nih.gov/pubmed/35422531
http://dx.doi.org/10.1038/s41591-022-01754-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117143/
https://www.ncbi.nlm.nih.gov/pubmed/35422531
http://dx.doi.org/10.1038/s41591-022-01754-x

Ejemplares similares